Quest Diagnostics Incorporated (DGX) Stock Price & How to Invest

Quest Diagnostics operates one of the largest clinical laboratory networks in the United States, processing billions of test results a year across a footprint of patient service centers, hospital and physician outreach relationships, and consumer-initiated testing. Its core Diagnostic Information Services segment spans routine testing (blood counts, cholesterol, metabolic panels) plus a growing base of advanced molecular and genomic diagnostics in oncology, neurology, women's health, and infectious disease. Scale, a national logistics network, and long-standing payer contracts are the company's main moats in a fragmented roughly $100 billion US lab market where Quest and Labcorp together hold the top tier.

The investment picture is that of a defensive healthcare-services business trading at a moderate valuation, with growth coming from organic volume, a steady cadence of tuck-in lab acquisitions, and a mix shift toward higher-value advanced testing. Q1 2026 showed revenue up about 9 percent and adjusted EPS up double digits, prompting raised full-year guidance, and Q2 2026 extended it: revenue rose about 10.2 percent to roughly $3.04 billion, net income reached about $320 million, and adjusted EPS of $3.12 beat the ~$2.82 consensus. The shares closed near $235 on October 16, 2026, up about 35 percent year to date, and third-quarter results are due on October 22, 2026, with consensus at about $2.87 of EPS on about $3.05 billion of revenue. The offsetting concern is reimbursement policy: Medicare rate schedules under PAMA and broader payer pressure cap pricing power, so the bull case rests on volume, efficiency (including AI and automation), and acquisitions rather than price increases.

The largest risk is reimbursement policy: Medicare rates under PAMA face potential cuts (a delay pushed reductions toward 2027, but a roughly 15 percent cut to hundreds of tests looms without permanent reform), and private-payer pricing pressure caps growth. Labor shortages in clinical lab technologists and molecular specialists can raise costs and constrain capacity. Increased FDA oversight of laboratory-developed tests could add compliance burden. Acquisition-led growth carries integration and overpayment risk, and a large debt load from deal activity adds interest expense. Finally, the business is competitive and partly commoditized, so share losses to Labcorp, hospital in-sourcing, or specialty labs would pressure both volume and margin.

15 analysts publish price targets on DGX, averaging $251.40 against a $235.00 price as of October 2026, or +7.0%. The published targets run from $232.00 to $265.00, a narrow spread, and the ratings split 9 buy, 8 hold, 0 sell. Over the last six months there have been 12 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full DGX forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Quest Diagnostics Incorporated. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Organic volume growth. Requisition volumes grew roughly 11 percent year over year in Q1 2026, with organic volume up about 10.8 percent. The most optimistic published target, $265.00, assumes this works close to its best case.

The case against. The largest risk is reimbursement policy: Medicare rates under PAMA face potential cuts (a delay pushed reductions toward 2027, but a roughly 15 percent cut to hundreds of tests looms without permanent reform), and private-payer pricing pressure caps growth. The most pessimistic target, $232.00, is roughly what DGX is worth if this bites instead.

Read the full bull and bear case on DGX, including what would have to change to break either one. Walnut is not an investment adviser.

No. Quest Diagnostics Incorporated (DGX) has not split its stock in the last 10 years. That is a statement about the window we check rather than about the company’s entire history, so an older split is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Quest Diagnostics Incorporated's investor relations page or your broker.

• Revenue (TTM): ~$11.56B, latest quarter +10.2% year over year
• Latest quarter (Q2 2026): Revenue ~$3.04B; adj. EPS $3.12 vs ~$2.82 estimate
• Margins (TTM): ~33.2% gross, ~15.3% operating, ~9.2% net
• Net income (TTM): ~$1.06B
• P/E (trailing / forward): ~25.0x / ~19.5x
• Dividend (annual / yield): ~$3.44 / ~1.4%
• Market cap: ~$25.9B at ~$235 per share
• 2026 consensus: Revenue ~$12.0B; EPS ~$11.20

After a roughly 35 percent gain in 2026, Quest trades near 19.5x forward earnings and about 14x EV/EBITDA as of October 16, 2026, still a moderate multiple for a business growing revenue around 10 percent. The dividend has risen for 15 consecutive years, most recently a 7.5 percent increase, and the payout is about a quarter of earnings. Third-quarter results on October 22, 2026 are the next test, with consensus at about $2.87 of EPS on about $3.05 billion of revenue and the 15 analysts tracked by Yahoo Finance holding a mean target of about $251.

Other names that sit close to DGX: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get DGX exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so DGX sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where DGX fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

DGX is a large-cap, dividend-raising lab-testing leader whose story hinges on steady volume growth, tuck-in acquisitions, and a mix shift toward advanced diagnostics, balanced against reimbursement policy risk. Through mid-2026 that story held: second-quarter revenue grew about 10% and adjusted EPS of $3.12 beat the ~$2.82 estimate.

Whether DGX is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is DGX a buy or a sell?, and where the stock could go from here in the DGX stock forecast.

For income investors, whether DGX pays a dividend and how the payout looks is covered in does DGX pay a dividend? And to weigh DGX against a peer, read the full side-by-side comparisons: DGX vs LH and DGX vs GH.